About Achilles TherapeuticsAchilles intends to develop next-generation personalized vaccines and adoptive T cell therapies for metastatic cancer by targeting truncal tumor neoantigens. The company is based on research at University College London, Cancer Research UK (CRUK) and the Francis Crick Institute.
Scientific Founder: Charles Swanton
CEO: Chris Ashton
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.